Abstract
SO-14 Randomized, phase 3 study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma (HCC): RATIONALE-301 age ≥65 years subgroup
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have